Open access · US-GOV via ClinicalTrials.gov Clinical trial

Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias

Authors not listed

Neurological Associates of West Los Angeles · 2022

Chronic inflammation Human Randomized controlled trial

Abstract

This study seeks to measure changes in cognition through verbal and visual test procedures and changes in biomarkers of Alzheimer's disease and inflammatory and metabolic parameters that can be measure in the central nervous system (CNS) with advanced neuroimaging techniques in patients treated with NE3107 (17a-ethynyl-androst-5-3b,7b,17b-triol).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-26 MST

Cite this

APA

Anonymous. (2022). Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias. <em>Neurological Associates of West Los Angeles</em>. https://clinicaltrials.gov/study/NCT05227820

Vancouver

Anonymous. Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias. Neurological Associates of West Los Angeles. 2022.

BibTeX

@misc{anon2022AntiIn, title = {Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias}, author = {Anonymous}, journal = {Neurological Associates of West Los Angeles}, year = {2022}, }